Ładuje się......
Novel therapeutics in multiple myeloma
Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2012
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3905954/ https://ncbi.nlm.nih.gov/pubmed/22507794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/102453312X13336169156131 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|